Any current/future new fundraising through debt or equity?

The transcript from the November 6, 2024 earnings call does not mention any current or planned fundraising through debt or equity. The company reported a net debt position of negative INR94.3 crores as of H1 FY25, indicating net cash surplus. They have generated free cash flow of INR45.8 crores in H1 FY25 and repaid debt of INR17.1 crores during this period. Focus remains on optimizing working capital and maintaining financial resilience without mention of new fund raises. Capital expenditure of INR103.5 crores was invested in facility upgrades in H1 FY25, funded internally. Overall, no indica

Any current/future capex/capital investment/strategic investment?

Neuland has invested INR 103.5 crores in capital expenditure during H1 FY25 focused on facility upgradation. The new production block in Unit 3 is on track for completion by FY25, with commercial production expected to commence in FY26. Investments are aimed at expanding capacity and capabilities, reflecting commitment to future growth. The company plans to invest in newer technologies like peptides to acquire newer projects and stay focused within the active ingredient space, particularly human health. Capital expenditures and capacity creation decisions are made after closely tracking market

Future growth expectations in sales/revenue/volumes?

FY25 is expected to be flat in revenue compared to FY24, with challenges due to product performance and market variables. Strong growth anticipated from FY26 onwards, driven by a significant order pipeline and customer demand. Specialty side growth will be driven by newly filed DMFs, peptides (e.g., Difelikefalin), and small molecules, mainly from 3 years onward. CMS business expected to grow beyond 50% revenue contribution, with increasing order books and expansion of relationships with innovator companies. Engagement with larger pharma companies with bigger pipelines is increasing, potential

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 is expected to be flat in terms of revenue and profitability compared to FY24, reflecting some execution delays and a cautious outlook. From FY26 onwards, Neuland anticipates healthy growth driven by a significant order pipeline and strong customer demand. Specialty business growth will be fueled by new molecules like peptides (e.g., Difelikefalin, Tirzepatide) and expansion in the CMS business. EBITDA margins in FY25 may see a slight drop from FY24's 27-28% levels but are expected to stabilize or improve depending on product mix and market conditions. Long-term growth is geared t

Current/ Expected Orderbook/ Pending Orders?

Management indicates a **significant order pipeline** and strong customer demand. They expect to **regain business momentum from FY26** despite FY25 likely being flat in terms of revenues. The CMS (Contract Manufacturing Services) business order book is described as **strong and growing**, with expectations of high growth in FY26. New business components for the CDMO segment are **on track**, though some execution timings have shifted. The company maintains close engagement with customers to keep projections and capital expenditure aligned with actual orders rather than market rhetoric. Overal

Neuland Laboratories LtdQ2 FY25Pharmaceuticals & Biotechnology

Neuland Laboratories Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹19,700P/E: 50.8Market Cap: ₹25.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

FY25 is expected to be flat in revenue compared to FY24, with challenges due to product performance and market variables.
Strong growth anticipated from FY26 onwards, driven by a significant order pipeline and customer demand.
Specialty side growth will be driven by newly filed DMFs, peptides (e.g., Difelikefalin), and small molecules, mainly from 3 years onward.
CMS business expected to grow beyond 50% revenue contribution, with increasing order books and expansion of relationships with innovator companies.
Engagement with larger pharma companies with bigger pipelines is increasing, potentially leading to more new business opportunities.
Long-term focus on high-value molecules, newer technologies, and capacity expansion to sustain growth.
Business outlook is cautiously optimistic with confidence in maintaining or improving growth over the next 5 years.

Margin guidance

Category 4

FY25 is expected to be flat in terms of revenue and profitability compared to FY24, reflecting some execution delays and a cautious outlook.
From FY26 onwards, Neuland anticipates healthy growth driven by a significant order pipeline and strong customer demand.
Specialty business growth will be fueled by new molecules like peptides (e.g., Difelikefalin, Tirzepatide) and expansion in the CMS business.
EBITDA margins in FY25 may see a slight drop from FY24's 27-28% levels but are expected to stabilize or improve depending on product mix and market conditions.
Long-term growth is geared towards focusing on high-value molecules, technology investments, and expanding capacity with new production blocks coming online by FY26.
Earnings per share in Q2FY25 was INR 24.9, down from INR 89.1 in Q2FY24, reflecting near-term pressures, but management is optimistic about regaining momentum post-FY25.

See what Neuland Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript from the November 6, 2024 earnings call does not mention any current or planned fundraising through debt or equity.
The company reported a net debt position of negative INR94.3 crores as of H1 FY25, indicating net cash surplus.
They have generated free cash flow of INR45.8 crores in H1 FY25 and repaid debt of INR17.1 crores during this period.
Focus remains on optimizing working capital and maintaining financial resilience without mention of new fund raises.
Capital expenditure of INR103.5 crores was invested in facility upgrades in H1 FY25, funded internally.
Overall, no indications or plans for new equity or debt fundraising were discussed in the call.

Order book

Yes

Management indicates a significant order pipeline and strong customer demand.
They expect to regain business momentum from FY26 despite FY25 likely being flat in terms of revenues.
The CMS (Contract Manufacturing Services) business order book is described as strong and growing, with expectations of high growth in FY26.
New business components for the CDMO segment are on track, though some execution timings have shifted.
The company maintains close engagement with customers to keep projections and capital expenditure aligned with actual orders rather than market rhetoric.
Overall outlook is cautiously optimistic, aiming to leverage investments in capacity expansion and maintain agility to meet demand.

See what Neuland Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Neuland has invested INR 103.5 crores in capital expenditure during H1 FY25 focused on facility upgradation.
The new production block in Unit 3 is on track for completion by FY25, with commercial production expected to commence in FY26.
Investments are aimed at expanding capacity and capabilities, reflecting commitment to future growth.
The company plans to invest in newer technologies like peptides to acquire newer projects and stay focused within the active ingredient space, particularly human health.
Capital expenditures and capacity creation decisions are made after closely tracking market realities and customer preferences.
The company emphasizes balancing growth with profitability through constant optimization of costs and processes to ensure long-term sustainability.
These investments are aligned with Neuland’s core principles of customer focus, agility, and operational excellence to seize growth opportunities from FY26 onwards.

Track Neuland Laboratories Ltd — get its next earnings analysis in your feed

How does Neuland Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNeuland Laboratories Ltd

Rev 3Mar 4

See where Neuland Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Neuland Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Neuland Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Neuland Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →